Patients with lower-risk myelodysplastic syndromes (MDS) experienced strong responses with fewer side effects when treated with a five-day azacitidine compared to shorter durations of azacitidine or decitabine. Final data from the trial was presented by Ian Bouligny, M.D., assistant professor of Leukemia.
“For patients with lower-risk MDS, a five-day duration of azacitidine was safe and effective, showing improved event-free survival and overall survival compared to three-day durations of azacitidine or decitabine,” Bouligny said. “We’ve seen firsthand how this approach improves outcomes and enhances the overall treatment experience for our patients in clinic.”